Hanmi's Collaboration with Gilead on Encequidar
Hanmi Pharm and Health Hope Pharma (HHP) have entered into a significant collaboration with Gilead Sciences, Inc. to grant exclusive licensing rights for Encequidar. This agreement marks a notable milestone in the realm of oral drug delivery, demonstrating the capabilities of Hanmi's proprietary Orascovery™ platform.
Understanding Encequidar and Its Potential
Encequidar, a P-glycoprotein (P-gp) inhibitor, plays a crucial role in converting injectable medications into convenient oral formulations. This transformation is made possible through Hanmi's innovative Orascovery™ technology, which offers a streamlined method for drug delivery and enhances patient accessibility. By leveraging this technology, the collaboration aims to open new horizons in treating various conditions, particularly in virology.
Key Terms of the Agreement
Under the terms of the licensing agreement, Hanmi and HHP are providing Gilead with exclusive global rights to develop Encequidar further. This partnership includes drug supply commitments, technical know-how sharing, and active involvement as key project partners. Both Hanmi and HHP will receive an upfront payment, as well as potential milestones related to development, regulatory approvals, and sales—coupled with royalties based on net sales.
Statements from Company Leaders
Dr. Dennis Lam, founder of HHP, expressed enthusiasm regarding this partnership, stating, "We are thrilled about the agreement with Gilead and the opportunities it presents. This reflects the exceptional potential of Encequidar and emphasizes our commitment to innovation in the biotech field."
Jae-Hyun Park, CEO of Hanmi Pharm, also shared insights, saying, "This collaboration validates our expertise and innovation in formulation technology. We look forward to expanding our strategic partnerships to enhance patient access globally." The partnership showcases Hanmi's strengths and marks a substantial step in developing oral formulations capable of transforming treatment approaches.
Future Prospects for Oraxol
Historically, Hanmi out-licensed Encequidar alongside the oral anticancer medication Oraxol to Athenex. However, after Athenex faced insolvency, the rights shifted to HHP. Currently, HHP is positioning Oraxol through clinical trials in the U.S. and other regions, aiming to launch it sequentially across Europe, Asia, and back into the U.S. market. This trajectory outlines the ambitious plans to not only develop Encequidar but also enhance the availability of Oraxol, thus reaffirming Hanmi’s position in the competitive biotech landscape.
Contact Information
If you're interested in learning more about Hanmi Pharm's innovative work or their collaboration with Gilead, you can visit their official website at www.hanmipharm.com.
You can also get in touch via LinkedIn: Hanmi on LinkedIn or contact them at innovation@hanmi.co.kr, or call +08-2-410-0467.
Frequently Asked Questions
What is the significance of the collaboration between Hanmi and Gilead?
The collaboration aims to enhance the development and commercialization of Encequidar, showcasing Hanmi's innovative oral drug delivery technology.
What is Orascovery™ technology?
Orascovery™ is Hanmi's proprietary platform designed to convert injectable drugs into effective oral formulations, improving patient accessibility.
Who will benefit from the licensing agreement?
This agreement is expected to benefit patients by providing easier oral medication options, while also offering financial benefits to Hanmi and HHP through royalties and milestone payments.
How does Encequidar function?
Encequidar serves as a P-gp inhibitor, helping to enhance the absorption of oral drugs by overcoming barriers to drug delivery within the body.
What are the future plans for Oraxol?
HHP is currently conducting clinical trials for Oraxol and plans to expand its launch across various global markets following successful outcomes.
